https://orcid.org/0000-0002-3640-3472
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Danielle Brazel, Shannon Zhang & Misako Nagasaka. (2022) Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer: Targets and Therapy 13, pages 33-45.
Read now
Read now
Toshio Fujino, Kenichi Suda & Tetsuya Mitsudomi. (2021) Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer: Targets and Therapy 12, pages 35-50.
Read now
Read now
Articles from other publishers (19)
Mohamed W. Attwa, Haitham AlRabiah, Ali S. Abdelhameed & Adnan A. Kadi. (2023) A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver Microsomes: Assessment of Metabolic Stability Using In Vitro Metabolic Incubation and In Silico Software Analysis. Separations 10:8, pages 450.
Crossref
Crossref
George Mihai Nitulescu, Gheorghe Stancov, Oana Cristina Seremet, Georgiana Nitulescu, Dragos Paul Mihai, Cosmina Gabriela Duta-Bratu, Stefania Felicia Barbuceanu & Octavian Tudorel Olaru. (2023) The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies. Molecules 28:14, pages 5359.
Crossref
Crossref
Hui Xia, Junhua Zhang, Tong Chen, Mingzhao Wang, Dongna Chen, Tongguo Si & Yutao Liu. (2023)
Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study
. Cancer Medicine 12:13, pages 14015-14024.
Crossref
Crossref
Mingxing Yang, Yuanli You, Xiuqing Wang & Wen Dong. (2023) I-125 seeds brachytherapy combined with immunotherapy for MET amplification in non-small cell lung cancer from clinical application to related lncRNA mechanism explore: a case report. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Pengyun Li, Changkai Jia, Zhiya Fan, Xiaotong Hu, Wenjuan Zhang, Ke Liu, Shiyang Sun, Haoxin Guo, Ning Yang, Maoxiang Zhu, Xiaomei Zhuang, Junhai Xiao, Zhibing Zheng & Song Li. (2023) Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. Acta Pharmaceutica Sinica B 13:6, pages 2715-2735.
Crossref
Crossref
Xingsheng Hu, Xinge Cui, Ziping Wang, Yunpeng Liu, Ying Luo, Wei Zhong, Hui Zhao, Mengxing Yao, Da Jiang, Mingxia Wang, Minjiang Chen, Xin Zheng, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu, Bei Hu, Xiaohong Han & Yuankai Shi. (2023) Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer 23:1.
Crossref
Crossref
Rui Sun, Zhizhong Wang, Jiuzhou Zhao, Pengfei Ren, Jie Ma & Yongjun Guo. (2023)
Optimized Detection of Unknown
MET
Exon 14 Skipping Mutations in Routine Testing for Patients With Non–Small-Cell Lung Cancer
. JCO Precision Oncology:7.
Crossref
Crossref
Jiajia Wu & Zhenghong Lin. (2022) Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. International Journal of Molecular Sciences 23:23, pages 15056.
Crossref
Crossref
Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang & Weimin Li. (2022) Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh & Tetsuya Mitsudomi. (2022) Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Yulin Ren, Lei Cao, Minli You, Jingcheng Ji, Yan Gong, Hui Ren, Feng Xu, Hui Guo, Jie Hu & Zedong Li. (2022) “SMART” digital nucleic acid amplification technologies for lung cancer monitoring from early to advanced stages. TrAC Trends in Analytical Chemistry 157, pages 116774.
Crossref
Crossref
Leila Asadollahi, Amin Mahoutforoush, Seyed Sina Dorreyatim, Tannaz Soltanfam, Ana Cláudia Paiva-Santos, Diana Peixoto, Francisco Veiga, Hamed Hamishehkar, Mahdi Zeinali & Soheil Abbaspour-Ravasjani. (2022) Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation. International Journal of Pharmaceutics 624, pages 122027.
Crossref
Crossref
Igor P. Oscorbin, Maria A. Smertina, Ksenia A. Pronyaeva, Mikhail E. Voskoboev, Ulyana A. Boyarskikh, Andrey A. Kechin, Irina A. Demidova & Maxim L. Filipenko. (2022) Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer. Cancers 14:6, pages 1458.
Crossref
Crossref
Takamasa Koga, Kenichi Suda & Tetsuya Mitsudomi. (2022) Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer. Cancer Science 113:3, pages 815-827.
Crossref
Crossref
Jiaojiao Yu, Lijing Zhang, Jun Peng, Richard Ward, Peiqi Hao, Jiwei Wang, Na Zhang, Yang Yang, Xiaoxi Guo, Cheng Xiang, Su An & Tian-Rui Xu. (2022) Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochemical Pharmacology 195, pages 114864.
Crossref
Crossref
Paulina Terlecka, Paweł Krawczyk, Anna Grenda & Janusz Milanowski. (2021) MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review. Journal of Personalized Medicine 11:12, pages 1370.
Crossref
Crossref
Shuta Ohara, Kenichi Suda & Tetsuya Mitsudomi. (2021) Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations. Cells 10:2, pages 354.
Crossref
Crossref
Rashmi Shah, Deepu Alex & Zhaolin Xu. (2021)
MET
Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances
. Oncology & Hematology Review (US) 16:2, pages 100.
Crossref
Crossref
Hang-Ping Yao, Xiang-Min Tong & Ming-Hai Wang. (2021) Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase. Drug Discovery Today 26:1, pages 106-121.
Crossref
Crossref